This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • c-Met Second-Line Hepatocellular Carcinoma
Clinical trial

c-Met Second-Line Hepatocellular Carcinoma

Read time: 1 mins
Last updated:14th Apr 2014

This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A liver function who have failed sorafenib treatment.

Category Value
Study start date 2014-04-14

View full details